Par Acquisition Of Kali Will Help Boost Product Offerings 50% In Two Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Par will pay $135 mil. for the New Jersey-based generic drug firm. The combined company will have 37 pending ANDAs, including first-to-file application for generic version of J&J's Ultracet.
You may also be interested in...
FDA Rescinds Zofran ODT ANDA Approval
A prior court decision that Par's ondansetron infringes an unexpired GSK patent prompts FDA to revoke approval.
FDA Rescinds Zofran ODT ANDA Approval
A prior court decision that Par's ondansetron infringes an unexpired GSK patent prompts FDA to revoke approval.
Ultracet Generics Launch: Par Goes "At Risk," Ivax Has "Authorized" Generic
Patent litigation between Par and J&J is pending in Newark, N.J. federal court. Par received ANDA approval for the tramadol/acetaminophen combination the same day the 30-month stay expired.